WO2013165972A3 - Anticorps anti-virus hépatite b et applications associées - Google Patents

Anticorps anti-virus hépatite b et applications associées Download PDF

Info

Publication number
WO2013165972A3
WO2013165972A3 PCT/US2013/038802 US2013038802W WO2013165972A3 WO 2013165972 A3 WO2013165972 A3 WO 2013165972A3 US 2013038802 W US2013038802 W US 2013038802W WO 2013165972 A3 WO2013165972 A3 WO 2013165972A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
sample
virus
detecting
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/038802
Other languages
English (en)
Other versions
WO2013165972A2 (fr
Inventor
Shuji Sato
Sean Andre BEAUSOLEIL
Wan Cheung CHEUNG
Roberto D. POLAKIEWICZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Signaling Technology Inc
Original Assignee
Cell Signaling Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signaling Technology Inc filed Critical Cell Signaling Technology Inc
Publication of WO2013165972A2 publication Critical patent/WO2013165972A2/fr
Publication of WO2013165972A3 publication Critical patent/WO2013165972A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps anti-virus hépatite B et des méthodes de traitement, de prophylaxie, de détection et de diagnostic associées.
PCT/US2013/038802 2012-04-30 2013-04-30 Anticorps anti-virus hépatite b et applications associées Ceased WO2013165972A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261640361P 2012-04-30 2012-04-30
US61/640,361 2012-04-30
US201361787143P 2013-03-15 2013-03-15
US61/787,143 2013-03-15

Publications (2)

Publication Number Publication Date
WO2013165972A2 WO2013165972A2 (fr) 2013-11-07
WO2013165972A3 true WO2013165972A3 (fr) 2014-02-27

Family

ID=49515018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/038802 Ceased WO2013165972A2 (fr) 2012-04-30 2013-04-30 Anticorps anti-virus hépatite b et applications associées

Country Status (1)

Country Link
WO (1) WO2013165972A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
US10307480B2 (en) 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP3324996A4 (fr) * 2015-07-22 2019-04-17 Scholar Rock, Inc. Protéines de liaison à gdf11 et leurs utilisations
PT3922645T (pt) 2015-09-15 2025-05-29 Scholar Rock Inc ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR20210082548A (ko) 2016-06-13 2021-07-05 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
WO2018039514A1 (fr) * 2016-08-25 2018-03-01 Vanderbilt University Anticorps pour la neutralisaton du virus ebola.
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
CN116917318A (zh) * 2020-11-20 2023-10-20 法国国家健康和医学研究院 抗cd25抗体
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011495A1 (fr) * 1992-11-06 1994-05-26 Sandoz, Ltd. Production d'anticorps monoclonaux humains actifs contre l'antigene de surface de l'hepatite b
WO2004050683A2 (fr) * 2002-12-02 2004-06-17 Abgenix, Inc. Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
US20080152658A1 (en) * 2005-04-18 2008-06-26 Shlomo Dagan Stabilized Anti-Hepatitis B (Hbv) Antibody Formulations
WO2012017003A1 (fr) * 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Protéine de fusion anticorps anti-cmh cytokine antivirale

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011495A1 (fr) * 1992-11-06 1994-05-26 Sandoz, Ltd. Production d'anticorps monoclonaux humains actifs contre l'antigene de surface de l'hepatite b
WO2004050683A2 (fr) * 2002-12-02 2004-06-17 Abgenix, Inc. Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
US20080152658A1 (en) * 2005-04-18 2008-06-26 Shlomo Dagan Stabilized Anti-Hepatitis B (Hbv) Antibody Formulations
WO2012017003A1 (fr) * 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Protéine de fusion anticorps anti-cmh cytokine antivirale

Also Published As

Publication number Publication date
WO2013165972A2 (fr) 2013-11-07

Similar Documents

Publication Publication Date Title
WO2014015194A3 (fr) Procédés de détection et de mesure d'agrégation
WO2013070776A8 (fr) Anticorps neutralisant la gp41 et leur utilisation
WO2012100235A3 (fr) Systèmes et procédés de maximisation d'utilisation d'échantillon
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
WO2014143343A8 (fr) Anticorps monoclonaux à domaine de liaison à un lipide du cœur de vhc
WO2014028378A3 (fr) Procédés et systèmes de détection de composants biologiques
WO2012129164A3 (fr) Biocapteur
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
BR112012016119A2 (pt) detecção de carga biológica viva com o uso de micropartículas
EP3933406A3 (fr) Anticorps pour rispéridone et utilisation associée
WO2012054588A3 (fr) Dispositifs à conduits et procédés de détection et de traitement d'analytes
EP2839266A4 (fr) Procédés et systèmes pour la détection d'un analyte ou le classement d'un échantillon
EP2798350A4 (fr) Procédés et systèmes de détection de pathogène dans un prélèvement biologique
WO2014031668A3 (fr) Anticorps dirigés contre la quétiapine et leur utilisation
WO2014031640A3 (fr) Anticorps dirigés contre l'aripiprazole et leur utilisation
WO2014031662A3 (fr) Anticorps dirigés contre l'olanzapine et leur utilisation
MX2019011702A (es) Ensayos de inmunogenicidad mejorados.
MX2015004419A (es) Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables.
EP3004375A4 (fr) Biocapteurs peptidiques sensibles à une protéase et procédés de détection d'analyte
EA201691091A1 (ru) Диагностические реагенты для улучшенной in vivo или in vitro клеточно-опосредованной иммунологической диагностики туберкулеза
WO2012032512A3 (fr) Procédés et kits pour la détection d'une infection chez des sujets présentant de faibles teneurs en anticorps spécifiques
GB201119585D0 (en) Assay
WO2011120015A3 (fr) Procédé et système d'épitope de phage couplé à une particule
WO2014145243A3 (fr) Essai d'analyse de fusion à haute résolution pour la détection d'adn viral
WO2012114312A3 (fr) Témoin positif interne exogène

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13784796

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13784796

Country of ref document: EP

Kind code of ref document: A2